三三九咳散治疗咳嗽变异性哮喘的临床与实验研究

Clinical and experimental researches on treating CVA with Sansanjiu Kesan granula

目的:观察三三九咳散治疗咳嗽变异性哮喘的临床疗效,评价其安全性。方法:将符合咳嗽变异性哮喘诊断标准的98例患者采用随机、阳性平行对照的方法,分为治疗组51例,对照组47例。治疗组口服三三九咳散颗粒,对照组予酮替芬口服,两组同时喷吸普米克气雾剂。14d为1个疗程,观察2个疗程。并随访1年,观察远期疗效。结果:治疗组总有效率达90.20%,对照组总有效率为80.85%,经x2统计两组疗效比较(P<0.05),证实治疗组疗效优于对照组。在咯痰、喘息、口干咽燥等方面,治疗组疗效优于对照组(P<0.05),两组治疗期间均未发生不良反应。结论:三三九咳散是治疗咳嗽变异性哮喘的有效方剂,值得临床推广和应用。

Objective： To investigate the clinical effect of Sansanjiu Kesan granula in treating CVA and evaluate its safety. Methods： 98 patients of CVA were randomly divided into two groups, 51 in the treatment group and 47 in the control group. The treatment group was orally given Sansanjiu Kesan granula, while the control group was orally given Ketotifen. In addition, both groups were given Pulmicort aerosol. 14 days for a treatment course. The clinical efficacy after two treatment courses were investigated and the prostecdtive efficacy were follow-up visited for a year. Results： The total efficacy rates of the treatment gryup and the control group were 90.20% and 80.85% respectively, with a significant difference （P〈0.05）. The treatment group displayed better effect on improving the symptoms of / stethocatharsis, gasping and dry mouth （P〈0.05）. No side effects were observed in b^th groups. Conclusion： Sansanjiu Kesan granula is effective in treating CVA, worth a wide clinical application. ｜